A unique collection of 3010 inhibitors for research in cell signaling, high throughput screening (HTS) and high content screening (HCS) for new drugs; Bioactivity and safety confirmed by pre-clinical research and clinical trials, and some of them are approved by FDA; Covers various major targets including MAPK, PI3K, JAK, HDAC, VEGFR, CDK, etc.; Detailed compound information with structure, target, activity, IC50 value, and biological activity description; Structurally diverse, medicinally active, and cell permeable; NMR and HPLC validated to ensure high purity and quality;
